SCHEMBL16100818

SCHEMBL16100818

CC(=O)N1CCC(Oc2ccc3c(c2)c(CN(C)CCN(C)C(=O)O)nn3S(=O)(=O)c2ccc(C)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 4/20 0.41
▸ CCR3 P51677 4/20 0.41
▸ KCNH2 Q12809 2/20 0.41
▸ POLB P06746 1/20 0.40
▸ RORC P51449 1/20 0.38
▸ PTGDR2 Q9Y5Y4 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HTR6 P50406 3/20 0.35
▸ HRH3 Q9Y5N1 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ LSS P48449 1/20 0.34
▸ F10 P00742 2/20 0.34
▸ PRSS1 P07477 2/20 0.34
▸ PRSS2 P07478 2/20 0.34
▸ PRSS3 P35030 2/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ PROKR1 Q8TCW9 1/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ PLG P00747 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16119961 0.91 HRH1 (0.38) HRH1CCR3KCNH2POLBRORC
SCHEMBL16100519 0.81 PTGDR2 (0.35) HRH1CCR3KCNH2RORCPTGDR2
SCHEMBL16100251 0.80 HTR6 (0.38) PTGDR2MEN1KMT2AHTR6MAPT
SCHEMBL16100001 0.78 PTGDR2 (0.35) HRH1CCR3KCNH2RORCPTGDR2
SCHEMBL16100520 0.76 CYP4F2 (0.41) POLBRORCHRH3F10PRSS1
SCHEMBL17457576 0.73 HTR6 (0.45) HTR6
SCHEMBL17457571 0.71 HTR6 (0.36) PTGDR2MEN1KMT2AHTR6MAPT
SCHEMBL16120051 0.68 CYP4F2 (0.38) POLBHRH3
SCHEMBL16220677 0.66 EPHX2 (0.56) HRH1CCR3POLBRORCHRH3
SCHEMBL16100512 0.66 CYP4F2 (0.40) POLBRORCHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed
EP-2970220-A2 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-20 — — EP disclosed
WO-2014153235-A2 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HRH1 1278/4885CCR3 4422/4885KCNH2 4710/4885
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HRH1 1278/4885CCR3 4422/4885KCNH2 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback